| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DCC3250 | Mbx2546 | Novel specific inhibitor of HA-mediated viral entry, inhibiting HPAI H5N1 virus strain A/Hong Kong/H5N1 |
|
| DCC3251 | Mc1220 | Topical nonnucleoside reverse transcriptase inhibitor, partially preventing vaginal RT-SHIV infection of macaques |
|
| DCC3252 | Mc-1353 | Potent and HDAC class I-selective inhibitor |
|
| DCC3253 | Mc1420 | Novel potent acetylcholinesterase (AChE) inhibitor |
|
| DCC3254 | Mc-1-f2 | The first inhibitor of forkhead Box Protein C2 (FOXC2) |
|
| DCC3255 | Mc2050 | Novel selective PARP1 inhibitor, inhibitng apoptosis and blocking poly ADP-ribosylation of histone H1 in hydrogen peroxide treated SH-SY5Y neuroblastoma cells |
|
| DCC3256 | Mc2392 | Novel hybrid retinoid-HDAC inhibitor |
|
| DCC3257 | Mc-70 Hydrochloride | Potent P-gp inhibitor with good selectivity towards BCRP pump (EC50 values 0.05 μM, 0.69 μM, 9.3 μM, and 73 μM for Caco-2, MDR1, MRP1, and BCRP inhibition, respectively) |
|
| DCC3258 | Mca-13 | Novel neurotropic agent |
|
| DCC3259 | Mca-yvadapk(dnp)-oh | Specific and highly fluorescent substrate for caspase-1, also acting as a substrate for caspase-4 |
|
| DCC3260 | Mcc1019 | Novel selective inhibitor of the Polo-box domain of Polo-like kinase 1 (PLK1) |
|
| DCC3261 | Mcc1189 | First-in-class inhibitor of MFS efflux pump CaMdr1p |
|
| DCC3262 | Mcc-134 | Novel inverse agonist for the pancreatic-type ATP-sensitive K channel as vascular relaxing agent |
|
| DCC3263 | MCC950 free acid Featured | Potent and selective inhibitor of NLRP3, reducing interleukin-1β (IL-1β) production in vivo and attenuating the severity of experimental autoimmune encephalomyelitis (EAE) |
|
| DCC3264 | Mc-doxhzn | Albumin-binding prodrug of Doxorubicin |
|
| DCC3265 | Mcg315 | Novel potent F508del-CFTR corrector, modulating poly-ADP ribose polymerase 3 and poly-ADP ribose polymerase 16 activities |
|
| DCC3266 | Mci-225 | Selective NA reuptake inhibitor with 5-HT3 receptor antagonism |
|
| DCC3267 | Mcl0527-3 | Novel inhibitor of p53-MDM2 interaction |
|
| DCC3268 | Mcl-1 Degrader C3 | Novel potent and selective degrader of Mcl-1 |
|
| DCC3269 | Mcl-1 Inhibitor-11 | Novel reversible covalent inhibitor for Mcl-1 with improved water solubility than Mcl-1 Inhibitor-5 |
|
| DCC3270 | Mcl-1 Inhibitor-39 | Novel selective Mcl-1 inhibitor |
|
| DCC3271 | Mcl-1 Inhibitor-5 | The first reversible covalent inhibitor for Mcl-1, a protein-protein interaction (PPI) target |
|
| DCC3272 | Mcl1-in-1 | Novel potent and selective inhibitor of the apoptosis regulating proteins Mcl-1 |
|
| DCC3273 | Mcmmad Featured | Novel mc (maleimidocaproyl) linker plus MMAD (Monomethylauristatin D) to be used for prepare antibodies conjugates via cysteine-capped mechanism |
|
| DCC3274 | Mct4-in-18n | Novel highly selective inhibitor of monocarboxylate transporter 4 (MCT4/SLC16A3), resulting in lactate efflux inhibition and reduction of cellular viability in MCT4 high expressing cells |
|
| DCC3275 | Mcule-5948770040 | Novel SARS-CoV-2 Main Protease (Mpro) inhibitor, binding to Subsites S1 and S2 (Kd=1.3 µM) |
|
| DCC3276 | Md-222 | First-in-class highly potent PROTAC degrader of MDM2 |
|
| DCC3277 | Md-39-am | Diuretic agent, impling an increase in the Na+ excretion and showing antihypertensive effect |
|
| DCC3278 | Mdc-1112 | Novel valproic acid (VPA) derivative, as a potent STAT3 inhibitor |
|
| DCC3279 | Mdcccl1636 | Novel partial PPARgamma ligand, displaying partial agonist activity in biochemical and cell-based transactivation assays, and reversed insulin resistance |
|
